For decades, malaria prevention has relied on a set of practical defenses: insecticide-treated bed nets, indoor spraying, preventive medicines and quick access to diagnosis and treatment. In January 2024, Cameroon added another tool to that effort. It became the first country to include a malaria vaccine in its routine childhood immunization program.
The step was both a public-health milestone and a change in how a long-running scientific project reaches families. A vaccine cannot replace bed nets or treatment, and it does not prevent every infection. But it gives health workers another way to reduce children’s risk from a disease that remains a major threat in many parts of the world.
From vaccine research to a national program
The vaccine used in Cameroon’s launch was RTS,S, also known by the brand name Mosquirix. Its introduction followed years of research and a pilot program in Ghana, Kenya and Malawi, which began in 2019. The World Health Organization (WHO) later recommended a second malaria vaccine, R21/Matrix-M, in October 2023. Together, the two vaccines offered countries more than one option as they planned how to bring malaria immunization into routine care.
These vaccines are designed to protect young children against malaria caused by the Plasmodium falciparum parasite. The parasite spreads through the bites of infected mosquitoes. After entering the body, it first travels to the liver before multiplying and causing illness. The vaccines help the immune system recognize the parasite early in that process. They are not a guaranteed shield, but they can reduce the likelihood of malaria and, importantly, severe disease.
Cameroon’s launch was not simply a matter of making a vaccine available. Routine immunization depends on the everyday machinery of health care: vaccine supplies, trained staff, safe storage, schedules that families can follow and communication that helps caregivers understand what a dose can—and cannot—do. Putting malaria vaccination into that system makes it possible for protection to be offered through familiar child-health services rather than as a one-off research intervention.
A new layer, not a replacement
The WHO’s guidance treats malaria vaccines as part of a wider prevention strategy. Children still need access to insecticide-treated nets and prompt testing and treatment when they become ill. In some settings, preventive medicines and measures to control mosquitoes are also important. The vaccine adds to those protections rather than asking families or health workers to choose just one.
That distinction matters. Calling a vaccine a “solution” can suggest that the disease is about to disappear, or that a vaccinated child no longer needs other safeguards. Neither would be a responsible conclusion. Malaria transmission differs across communities and seasons, and vaccination’s contribution will depend on how programs are delivered alongside other effective measures.
Instead, the optimistic part is more concrete: a vaccine developed through research and assessed by global health authorities has entered a country’s routine immunization program. That creates a path for eligible children to be reached through a public-health service designed to provide preventive care. It also gives health authorities experience with the planning, delivery and public communication required for a new kind of childhood vaccination.
Why the rollout is a scientific achievement
Malaria has proved difficult to address with a vaccine. The parasite’s life cycle is complex, and immunity to malaria does not work in the same straightforward way as immunity to some viral infections. The vaccines now recommended by WHO are the result of sustained work by researchers, manufacturers, public-health institutions and the communities involved in clinical studies and early implementation.
There is also a practical advantage in having two WHO-recommended malaria vaccines. A second product gives countries another option as supply and program needs are considered. WHO recommended R21/Matrix-M after reviewing evidence on its safety and effectiveness, and described both malaria vaccines as important tools for preventing disease in children. Their availability does not eliminate the challenge of getting doses to every child who could benefit, but it broadens the possibilities for national programs.
Cameroon’s first routine program marked a transition: malaria vaccination was no longer only a subject of clinical research or a pilot effort. It had become part of a country’s public-health calendar. That is a significant kind of progress—less dramatic than a single cure, perhaps, but built for repeated use through services families already rely on.
The measure of success will be what happens after a launch: whether vaccination reaches children, whether communities can access the full recommended course, and how well it works alongside nets, diagnosis and treatment. Those are continuing tasks, not reasons to overstate what the vaccine can do. But the beginning of routine vaccination in Cameroon is a genuine reason for optimism: science has delivered another evidence-based way to protect children from a serious disease, and health systems have begun putting it into practice.
